keyword
MENU ▼
Read by QxMD icon Read
search

Adjuvant sunitinib

keyword
https://www.readbyqxmd.com/read/28728992/retroperitoneal-lymphadenectomy-in-high-risk-non-metastatic-renal-cell-carcinoma-an-analysis-of-the-assure-ecog-acrin-2805-adjuvant-trial
#1
Benjamin T Ristau, Judi Manola, Naomi B Haas, Daniel Y C Heng, Edward M Messing, Christopher G Wood, Christopher J Kane, Robert S DiPaola, Robert G Uzzo
PURPOSE: Lymphadenectomy (LND) is a well-established practice in many urologic malignancies; however, its role in renal cell carcinoma (RCC) is less clear. Our primary objective was to determine whether LND impacted survival in patients with fully resected high-risk RCC. PATIENTS AND METHODS: Patients with fully resected high-risk, non-metastatic RCC were randomized to adjuvant sorafenib, sunitinib, or placebo in the Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma (ASSURE) trial...
July 17, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28685083/complete-response-to-second-line-chemotherapy-with-sunitinib-of-a-gastrointestinal-stromal-tumor-a-case-report
#2
Tsuyoshi Shirakawa, Tomoya Hirata, Kosuke Maemura, Toshiyuki Goto, Yoshiya Shimao, Kosuke Marutsuka, Yuji Ueda, Ikuo Kikuchi
Gastrointestinal stromal tumors (GISTs) are a type of sarcoma, and the most common mesenchymal tumor of the gastrointestinal tract. Systemic chemotherapy is recommended for unresectable or metastatic GISTs. Imatinib is an oral multitargeted receptor tyrosine kinase inhibitor that is effective as adjuvant chemotherapy for primary high-risk cases, and as palliative chemotherapy for unresectable or metastatic cases. For imatinib-resistant cases, second-line chemotherapy with sunitinib is recommended due to significantly longer median progression-free survival and higher response rates compared with a placebo...
July 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28680753/efficacy-of-vaccination-with-tumor-exosome-loaded-dendritic-cells-combined-with-cytotoxic-drug-treatment-in-pancreatic-cancer
#3
Li Xiao, Ulrike Erb, Kun Zhao, Thilo Hackert, Margot Zöller
Pancreatic cancer (PaCa) has a dismal prognosis and adjuvant immunotherapy frequently is of low efficacy due to immunosuppressive features of PaCa and PaCa-stroma. We here explored, whether the efficacy of vaccination with tumor-exosome (TEX)-loaded dendritic cells (DC) can be improved by combining with drugs affecting myeloid-derived suppressor cells (MDSC). Experiments were performed with the UNKC6141 PaCa line. UNKC6141 TEX-loaded DC were weekly intravenously injected, mice additionally receiving Gemcitabine (GEM) and/or ATRA and/or Sunitinib (Sun)...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28642820/intratumorally-injected-pro-inflammatory-allogeneic-dendritic-cells-as-immune-enhancers-a-first-in-human-study-in-unfavourable-risk-patients-with-metastatic-renal-cell-carcinoma
#4
Anna Laurell, Maria Lönnemark, Einar Brekkan, Anders Magnusson, Anna Tolf, Anna Carin Wallgren, Bengt Andersson, Lars Adamson, Rolf Kiessling, Alex Karlsson-Parra
BACKGROUND: Accumulating pre-clinical data indicate that the efficient induction of antigen-specific cytotoxic CD8+ T cells characterizing viral infections is caused by cross-priming where initially infected DCs produce an unique set of inflammatory factors that recruit and activate non-infected bystander DCs. Our DC-based immunotherapy concept is guided by such bystander view and accordingly, we have developed a cellular adjuvant consisting of pre-activated allogeneic DCs producing high levels of DC-recruiting and DC-activating factors...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28495808/comprehensive-genomic-profiling-of-esthesioneuroblastoma-reveals-additional-treatment-options
#5
Laurie M Gay, Sungeun Kim, Kyle Fedorchak, Madappa Kundranda, Yazmin Odia, Chaitali Nangia, James Battiste, Gerardo Colon-Otero, Steven Powell, Jeffery Russell, Julia A Elvin, Jo-Anne Vergilio, James Suh, Siraj M Ali, Philip J Stephens, Vincent A Miller, Jeffrey S Ross
BACKGROUND: Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant neoplasm of the olfactory mucosa. Despite surgical resection combined with radiotherapy and adjuvant chemotherapy, ENB often relapses with rapid progression. Current multimodality, nontargeted therapy for relapsed ENB is of limited clinical benefit. MATERIALS AND METHODS: We queried whether comprehensive genomic profiling (CGP) of relapsed or refractory ENB can uncover genomic alterations (GA) that could identify potential targeted therapies for these patients...
July 2017: Oncologist
https://www.readbyqxmd.com/read/28479237/adjuvant-therapy-for-high-risk-localized-kidney-cancer-emerging-evidence-and-future-clinical-trials
#6
REVIEW
Andrew T Lenis, Nicholas M Donin, David C Johnson, Izak Faiena, Amirali Salmasi, Alexandra Drakaki, Arie Belldegrun, Allan Pantuck, Karim Chamie
PURPOSE: We will review the literature on adjuvant therapies for patients with high-risk localized kidney cancer following surgical treatment. Two recently published prospective trials with conflicting results will be reconciled within the context of their respective designs. Finally, we will spotlight upcoming trials that use novel immunotherapy-based checkpoint inhibitors and have the potential to establish a new standard of care. MATERIALS AND METHODS: A PubMed search was performed for English language articles using the keywords "renal cell carcinoma," "kidney cancer," "immunotherapy," "targeted therapy," and "adjuvant therapy" published through January 2017...
May 4, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28427506/recent-advances-in-genitourinary-tumors-a-review-focused-on-biology-and-systemic-treatment
#7
REVIEW
Aránzazu González Del Alba, José Ángel Arranz, Javier Puente, María José Méndez-Vidal, Enrique Gallardo, Enrique Grande, Begoña Pérez-Valderrama, Enrique González-Billalabeitia, Martín Lázaro-Quintela, Álvaro Pinto, Nuria Lainez, Josep M Piulats, Emilio Esteban, José Pablo Maroto Rey, Jorge A García, Cristina Suárez
Updated information published up to 2016 regarding major advances in renal cancer, bladder cancer, and prostate cancer is here presented. Based on an ever better understanding of the genetic and molecular alterations that govern the initial pathogenic mechanisms of tumor oncogenesis, an improvement in the characterization and treatment of urologic tumors has been achieved in the past year. According to the Cancer Genome Atlas (ATLAS) project, alterations in the MET pathway are characteristics of type 1 papillary renal cell carcinomas, and activation of NRF2-ARE pathway is associated with the biologically distinct type 2...
May 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28286921/treatment-strategies-for-metastatic-neuroendocrine-tumors-of-the-gastrointestinal-tract
#8
REVIEW
Mauro Cives, Jonathan Strosberg
The therapeutic landscape of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) has evolved significantly in recent years. Current and emerging treatment options include somatostatin analogs, radiolabeled somatostatin analogs, the mTOR inhibitor everolimus, and the tyrosine kinase inhibitor sunitinib. Although high-quality data from phase III trials are lacking, cytotoxic agents are commonly used for the treatment of poorly differentiated neuroendocrine carcinomas and well-differentiated NETs originating in the pancreas...
March 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28278333/adjuvant-treatment-for-high-risk-clear-cell-renal-cancer-updated-results-of-a-high-risk-subset-of-the-assure-randomized-trial
#9
Naomi B Haas, Judith Manola, Janice P Dutcher, Keith T Flaherty, Robert G Uzzo, Michael B Atkins, Robert S DiPaola, Toni K Choueiri
Importance: Given recently published results of a 750-patient adjuvant sunitinib trial showing improved disease-free survival (DFS), the appropriate strategy for treating high-risk patients is unclear. We sought to determine whether there is improved disease-free survival benefit to taking the active drug in patients with high-risk (pT3, pT4, node-positive) clear cell renal cancer (ccRCC) in the ASSURE trial (adjuvant sunitinib or sorafenib vs placebo in resected unfavorable renal cell carcinoma [RCC]), the largest adjuvant trial published to date...
March 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28249133/adjuvant-sunitinib-in-renal-cell-carcinoma
#10
LETTER
Alain Ravaud
No abstract text is available yet for this article.
March 2, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28245539/-a-case-of-hydrocephalus-due-to-brain-metastasis-from-renal-cell-carcinoma-successfully-treated-with-axitinib
#11
Soichiro Shimura, Dai Koguchi, Satoru Minamida, Yoshinori Taoka, Masatsugu Iwamura
We report a case of hydrocephalus due to brain metastasis from renal cell carcinoma treated with axitinib. A 65-year-old man had undergone right radical nephrectomy for renal cell carcinoma in 2010. The pathological diagnosis indicated clear cell carcinoma G3, pT1a. After adjuvant treatment with interferon-α, computed tomography, in 2011, revealed multiple lung metastases. He was administered sorafenib. Because of progressive lung metastases, sunitinib was administered. The lung metastases were progressive and bone scan revealed multiple bone metastases...
January 2017: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/28143685/re-adjuvant-sunitinib-in-high-risk-renal-cell-carcinoma-after-nephrectomy
#12
Tobias Klatte
No abstract text is available yet for this article.
May 2017: European Urology
https://www.readbyqxmd.com/read/28133332/-multidisciplinary-treatment-for-high-risk-gist-of-the-stomach
#13
Tomo Ishida, Shigeyuki Tamura, Atsushi Takeno, Kohei Murakami, Yohei Nose, Ryota Mori, Yasuo Oneda, Ryuichi Kuwahara, Takuya Sakamoto, Atsushi Naito, Yoshiteru Katsura, Yoshiaki Ohmura, Yoshinori Kagawa, Yutaka Takeda, Takeshi Kato
A 59-year-old man underwent total gastrectomy(with D2 dissection)and cholecystectomy for gastric cancer and a submucosal tumor of the stomach. The specimen was immunohistochemically positive for c-kit, the Ki-67 label index was 10%, and the mitotic count was 20/HPF. Finally, the patient was diagnosed with high-risk gastrointestinal stromal cancer with normal type gastric cancer. After discharge from hospital, we started administration of TS-1 as adjuvant therapy for the gastric cancer. As multiple recurrences of the GIST in the abdomen developed, the patient underwent 3 radical local resections...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28104620/adjuvant-sunitinib-in-renal-cell-carcinoma-from-evidence-to-recommendation
#14
A Bex
No abstract text is available yet for this article.
April 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27993814/adjuvant-sunitinib-for-high-risk-resected-renal-cell-carcinoma-a-meta-analysis-of-assure-and-s-trac-trials
#15
B Gyawali, Y Ando
No abstract text is available yet for this article.
April 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27986369/updated-european-association-of-urology-guidelines-regarding-adjuvant-therapy-for-renal-cell-carcinoma
#16
Axel Bex, Laurence Albiges, Börje Ljungberg, Karim Bensalah, Saeed Dabestani, Rachel H Giles, Fabian Hofmann, Milan Hora, Markus A Kuczyk, Thomas B Lam, Lorenzo Marconi, Axel S Merseburger, Michael Staehler, Alessandro Volpe, Thomas Powles
The European Association of Urology Renal Cell Carcinoma (RCC) guidelines panel updated their recommendation on adjuvant therapy in unfavourable, clinically nonmetastatic RCC following the recently reported results of a second randomised controlled phase 3 trial comparing 1-yr sunitinib to placebo for high-risk RCC after nephrectomy (S-TRAC). On the basis of conflicting results from the two available studies, the panel rated the quality of the evidence, the harm-to-benefit ratio, patient preferences, and costs...
May 2017: European Urology
https://www.readbyqxmd.com/read/27930642/adjuvant-treatment-for-renal-cell-carcinoma-do-we-finally-have-a-major-breakthrough
#17
REVIEW
Devin N Patel, Robert A Figlin, Hyung L Kim
Clinical parameters can be used to identify patients at greatest risk for recurrence following nephrectomy for clinically localized renal cell carcinoma (RCC). Molecular tools are being developed to improve risk stratification. An increasing list of available treatments for metastatic RCC continues to provide hope that an effective adjuvant therapy will be identified for patients with high-risk, clinically localized disease. In a phase 3 adjuvant therapy trial (S-TRAC), sunitinib increased median disease-free survival in patients with clear cell RCC who were at very high risk...
November 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27928797/-changes-of-diagnosis-and-treatment-for-gastrointestinal-stromal-tumors-during-a-18-year-period-in-four-medical-centers-of-china
#18
Haibo Qiu, Peng Zhang, Xingyu Feng, Tao Chen, Xiaowei Sun, Jiang Yu, Zhijing Chen, Yong Li, Kaixiong Tao, Guoxin Li, Zhiwei Zhou
OBJECTIVE: To elucidate the historic and current diagnosis and treatment status of gastrointestinal stromal tumor (GIST) in the Chinese population based on four high volume databases. METHODS: Clinicopathological data of GIST patients with follow-up information between January 1998 and December 2015 from Sun Yat-sen University Cancer Center, Union Hospital of Huazhong University of Science and Technology, Southern Medical University Nanfang Hospital and Guangdong General Hospital were retrospectively analyzed...
November 25, 2016: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/27900022/conversion-of-aspergilloma-to-chronic-necrotizing-pulmonary-aspergillosis-following-treatment-with-sunitinib-a-case-report
#19
Yeon Wook Kim, Hyun Woo Lee, Jaeyoung Cho, Han-Sol Choi, Jungsil Lee, Sung Soo Park, Eun Young Heo, Kwang Nam Jin, Deog Kyeom Kim
Semi-invasive or invasive aspergillosis occurring following chemotherapy with sunitinib is a rare condition with unknown incidence and prognosis. Here, we report a case involving a 59-year-old male who had a history of underlying stable aspergilloma and was newly diagnosed with metastatic renal cell carcinoma. Following surgical resection for renal cell carcinoma and adjuvant chemotherapy with sunitinib for 8 months, the patient presented with hemoptysis. Chest computed tomography revealed an increased soft tissue mass and air crescent sign of the underlying aspergilloma, combined with consolidation and bronchial artery hypertrophy around the lesion...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27773485/sunitinib-as-adjuvant-therapy-for-renal-cell-carcinoma
#20
Holly Baker
No abstract text is available yet for this article.
October 20, 2016: Lancet Oncology
keyword
keyword
110017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"